Membrane Or Diffusion Barrier Patents (Class 424/424)
-
Patent number: 12201752Abstract: This invention pertains to systems and components useful for infusing medications such as insulin. Typically, the components are used to deliver insulin to a diabetic patient at a site of infusion over a period of time greater than 4 days. The system components typically comprise a cannula adapted for subcutaneous insertion into a diabetic patient. The system further comprises a fluid conduit adapted to deliver the insulin solution from a medication reservoir to the site of infusion and a depot in operable contact with the fluid conduit. The depot comprises selected materials including a site-loss mitigating agent (such as heparin) which inhibits inflammation at the site of infusion, and encapsulation of the cannula at the site of infusion. The site-loss mitigating agent is not premixed with the insulin, and instead is adapted to contact the insulin solution in the depot as the insulin solution flows from the medication reservoir to the site of infusion.Type: GrantFiled: October 12, 2021Date of Patent: January 21, 2025Assignee: Medtronic MiniMed, Inc.Inventors: Kiem H. Dang, Sarnath Chattaraj, Hsi C. Fusselman, Lance P. Hoffman, Guangping Zhang
-
Patent number: 12097090Abstract: There are described delivery devices for insertion into a body cavity of a target mammal, the delivery device comprising a resilient frame adapted to receive one or more moulded impregnated masses. The frame, together with the impregnated mass, are insertable, retainable and withdrawable from the intended body cavity. The impregnated mass or masses are attached to the frame to present substantially all of each face of the masses to exposure to a fluid of the body cavity when retained therein.Type: GrantFiled: July 11, 2016Date of Patent: September 24, 2024Assignee: Ulti Pharmaceuticals LimitedInventor: Michael Rathbone
-
Patent number: 12084642Abstract: A cell culture device comprising a container, at least one divider and a plurality of cell growth blocks located within the container. The divider separates the container into multiple compartments and is selectively permeable. The cell growth blocks are each independently removable from the container. Also disclosed is a cell growth block comprising a three dimensional scaffold located within a selectively permeable housing, a kit for a cell culture device and a method of culturing cells.Type: GrantFiled: February 6, 2017Date of Patent: September 10, 2024Assignee: REVIVOCELL LIMITEDInventor: Valon Llabjani
-
Patent number: 12059503Abstract: In this specification, a method for the manufacture of solid dosage forms is disclosed. The method includes extruding a plasticized matrix through an exit port of an extrusion channel to form one or more plasticized fibers, structuring said fibers to a three dimensional structural network by patterning on a translating or rotating stage, and solidifying the patterned structure.Type: GrantFiled: February 13, 2022Date of Patent: August 13, 2024Inventor: Aron H. Blaesi
-
Patent number: 12016327Abstract: An implantable device for encapsulating cells includes one or more cell encapsulation layers. Each of the cell encapsulation layers includes a first membrane that is semipermeable, a second membrane that is semipermeable, and a first plurality of weld lines. The second membrane is attached to the first membrane by the first plurality of weld lines. The first membrane, the second membrane, and the first plurality of weld lines define at least one cell channel for encapsulating cells. The cell encapsulation device is configurable between a collapsed configuration and an inflated configuration.Type: GrantFiled: March 15, 2018Date of Patent: June 25, 2024Assignee: BOSTON SCIENTIFIC MEDICAL DEVICE LIMITEDInventors: Aiden Flanagan, Matthew McEvaddy, Martin L Fawdry, Gary Duffy, Eamonn J. Tuohy
-
Patent number: 11931538Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.Type: GrantFiled: August 15, 2020Date of Patent: March 19, 2024Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Dustin Williams, Nicholas Ashton
-
Patent number: 11931453Abstract: Embodiments of the invention include devices, compositions and methods for the controlled release of therapeutic substances, such as drugs. Control over the rate of release of the therapeutic substances from the devices is achieved by the use of nanoporous membranes in which the pore size is matched to the molecular diameter of the therapeutic substances. Some embodiments of the invention achieve zero-order release by the use of membranes with a pore diameter that is more than five times the Stokes' diameter of the therapeutic substance released.Type: GrantFiled: September 7, 2021Date of Patent: March 19, 2024Assignee: Nano Precision Medical, Inc.Inventors: Adam D. Mendelsohn, Kathleen E. Fischer, Tomoyuki Yoshie, Wouter Roorda
-
Patent number: 11931482Abstract: The invention provides an auranofin-releasing antibacterial and antibiofilm polyurethane (PU) catheter coating. Auranofin is an antirheumatic drug with recently identified antimicrobial properties.Type: GrantFiled: March 18, 2020Date of Patent: March 19, 2024Assignees: BROWN UNIVERSITY, Rhode Island HospitalInventors: Anita Shukla, Beth Fuchs, Hanyang Liu, Eleftherios Mylonakis
-
Patent number: 11911584Abstract: A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.Type: GrantFiled: August 15, 2020Date of Patent: February 27, 2024Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Dustin Williams, Nicholas Ashton
-
Patent number: 11911034Abstract: Surgical methods involving cutting and sealing tissue include affixing a first adjunct material to tissue at a treatment site, such as by stapling the adjunct to tissue. A second adjunct material is applied to at least a portion of the first adjunct material such that the second adjunct material interacts with the first adjunct material to form a seal in an area of the tissue covered by at least one of the first and the second adjunct material. The resulting tissue sealing structure, which includes a combination of the two adjuncts, is believed to be superior to the sealing properties of either adjunct alone.Type: GrantFiled: February 22, 2021Date of Patent: February 27, 2024Assignee: Cilag GmbH InternationalInventors: Frederick E. Shelton, IV, Jason L. Harris, Bret W. Smith
-
Patent number: 11865093Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.Type: GrantFiled: July 13, 2018Date of Patent: January 9, 2024Assignees: University of Massachusetts, University of BathInventors: Randall Mrsny, Beth McCormick, Roland Ellwood Dolle
-
Patent number: 11860120Abstract: An IC includes a source region and a drain region in a semiconductor layer. A channel region is between the source region and the drain region. A sensing well is on a back surface of the semiconductor layer and over the channel region. An interconnect structure is on a front surface of the semiconductor layer opposite the back surface of the semiconductor layer. A biosensing film lines the sensing well and contacts a bottom surface of the sensing well that is defined by the semiconductor layer. A coating of selective binding agent is over the biosensing film and configured to bind with a cardiac cell.Type: GrantFiled: August 31, 2020Date of Patent: January 2, 2024Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD.Inventors: Tung-Tsun Chen, Yi-Hsing Hsiao, Jui-Cheng Huang, Yu-Jie Huang
-
Patent number: 11833244Abstract: A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.Type: GrantFiled: November 19, 2021Date of Patent: December 5, 2023Assignee: Gesea Biosciences Inc.Inventors: John H. Baillie, Ruth Baillie, George Blouin, Newsha Farahani, Christopher Marx
-
Patent number: 11701449Abstract: An injectable medical composition includes an acrylate and a solvent. The composition has a first viscosity at temperatures below body temperature and a second viscosity at body temperature. The first viscosity is lower than the second viscosity.Type: GrantFiled: November 16, 2022Date of Patent: July 18, 2023Assignee: QMARK MEDICAL INC.Inventors: Patrick H. Ruane, Sameer Sharma
-
Patent number: 11690807Abstract: An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer.Type: GrantFiled: May 20, 2019Date of Patent: July 4, 2023Assignee: Celanese EVA Performance Polymers LLCInventor: Christian Schneider
-
Patent number: 11590329Abstract: In another example, a bioresorbable implant for use in a nasal region includes one or more bioresorbable polymers, and a pharmaceutical composition coupled to the one or more bioresorbable polymers. A release rate of the pharmaceutical composition is related to a degradation rate of the one or more bioresorbable polymers.Type: GrantFiled: May 16, 2019Date of Patent: February 28, 2023Assignee: Spirox, Inc.Inventors: Gene Michal, Daniel L. Cox, Piyush Arora, Michael S. Mirizzi, Scott Baron
-
Patent number: 11497810Abstract: A system for administering biologically active substances produced by foaming techniques using compressed gases or supercritical fluids relates to a porous system containing biologically active substances. The system includes a polymer matrix of poly(D,L-lactic-co-glycolic acid) or a polymer mixture containing poly(D,L-lactic-co-glycolic acid) of an intrinsic viscosity of less than 0.5 dL/g with other biodegradable synthetic or semisynthetic polyesters, a release-regulating component (starch and derivatives), and at least one biologically active substance. The matrix is biodegradable with a solid or semisolid consistency and a homogeneous appearance. A method for producing these systems using foaming with compressed fluids, and the use for the production of implants and scaffolds having this system are also disclosed. Optionally, a porogenic agent can be used for the formation of macropores by thermal decomposition.Type: GrantFiled: July 12, 2016Date of Patent: November 15, 2022Assignee: UNIVERSIDADE DE SANTIAGO DE COMPOSTELAInventors: Carlos Garcia Gonzalez, Luis A Diaz Gomez, Carmen Alvarez Lorenzo, Angel J Concheiro Nine
-
Patent number: 11471419Abstract: Provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at least one cell. The improved survival and/or function of the at least one live cell in the microcapsule is compared to a live cell in a microcapsule in the absence of the compound capable of improving survival of the at least one cell. The first and second polymer may include alginate and the third polymer (used for the microsphere) may comprise PLGA. The compound may include a GLP-1 receptor agonist. Also provided are methods for producing such microcapsules; insulin delivery systems using the microcapsules, and methods to treat disease, such as diabetes, using the microcapsules.Type: GrantFiled: September 29, 2017Date of Patent: October 18, 2022Assignee: The Board of Trustees of the University of IllinoisInventors: Kyekyoon Kim, Hyungsoo Choi
-
Patent number: 11278498Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.Type: GrantFiled: November 5, 2020Date of Patent: March 22, 2022Assignee: Axial Therapeutics, Inc.Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
-
Patent number: 11213431Abstract: A tympanostomy tube includes a nitinol body having a first configuration and a second configuration. In the first configuration, the nitinol body has a first cylindrical shape defining a first end, a central region, a second end, a longitudinal axis, and a lumen extending longitudinally through the nitinol body. In the second configuration, the nitinol body is expanded and has a second cylindrical shape different than the first cylindrical shape and defines the first end, the central region, the second end, the longitudinal axis, and the lumen. A diameter of the lumen at one of the first end, the central region, and the second end is larger in the second configuration than the diameter of the lumen at the corresponding first end, central region, or second end in the first configuration.Type: GrantFiled: February 5, 2019Date of Patent: January 4, 2022Assignee: Ear Tech, LLCInventor: Michael H. Fritsch
-
Patent number: 11147903Abstract: A prosthesis for a synovial joint arthroplasty within a human body is provided.Type: GrantFiled: March 23, 2019Date of Patent: October 19, 2021Inventor: Dewey M. Sims, Jr.
-
Patent number: 11129791Abstract: Embodiments of the invention include devices, compositions and methods for the controlled release of therapeutic substances, such as drugs. Control over the rate of release of the therapeutic substances from the devices is achieved by the use of nanoporous membranes in which the pore size is matched to the molecular diameter of the therapeutic substances. Some embodiments of the invention achieve zero-order release by the use of membranes with a pore diameter that is more than five times the Stokes' diameter of the therapeutic substance released.Type: GrantFiled: November 29, 2018Date of Patent: September 28, 2021Assignee: NANO PRECISION MEDICAL, INC.Inventors: Adam D. Mendelsohn, Kathleen E Fischer, Tomoyuki Yoshie, Wouter E. Roorda
-
Patent number: 11077123Abstract: Methods of inhibiting bacterial conjugation, bacterial horizontal gene transfer or bacterial growth are disclosed. The methods comprise contacting bacteria with an effective amount of a bile acid or a bile salt, wherein the effective amount does not affect viability of the bacteria. A method of increasing susceptibility of bacteria to antibiotic treatment is also disclosed as well as methods of decontaminating a farm animal housing or a medical surface and methods of treating water. Also disclosed are compositions effective in inhibiting bacterial conjugation, bacterial horizontal gene transfer and bacterial growth.Type: GrantFiled: February 28, 2017Date of Patent: August 3, 2021Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.Inventors: Ohad Gal-Mor, Galia Rahav
-
Patent number: 11051900Abstract: Embodiments herein describe tools and instruments for holding, transferring, delivering, deploying an implantable device and methods and means of aseptically storing and shipping the implantable device including but not limited to a device case for protecting, housing and filling the device, a surgical sizer for preparing the implantable site, a deployer for transferring the implantable device from the device case and delivering or deploying the implantable device at the prepared implantable site.Type: GrantFiled: April 16, 2014Date of Patent: July 6, 2021Assignee: ViaCyte, Inc.Inventors: Vincent So, Erik Olson, Michael Scott, Chad Green, Giacomo Strollo, Gustavo Prado, Craig McGreevy, Laura Martinson, Donald Koenig
-
Patent number: 11039943Abstract: A bioabsorbable biomedical implant is disclosed. The implant includes a tubular scaffold comprising a plurality of interconnected polymer struts. The interconnected polymer struts defines a plurality of deformable cells. The polymer struts have an average thickness of no more than 120 ?m. Methods for making the bioabsorbable biomedical implant, including the methods for making the polymer materials for the tubular scaffold, are also disclosed.Type: GrantFiled: March 12, 2014Date of Patent: June 22, 2021Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor
-
Patent number: 11028023Abstract: The invention discloses a method for preparing mesoporous sound-absorbing material particles and mesoporous sound-absorbing material particles. The preparation method comprises the following steps. In step 1, sound-absorbing material powder and a templating agent are mixed with a binding agent and water to form sol slurry, the templating agent is an organic monomer or a linear polymer, and the templating agent has a purity greater than 95%. In step 2, the sol slurry is dropped into forming oil, and the droplets of the sol slurry are aged in the forming oil to form gel particles. In step 3, the gel particles are taken out from the forming oil and the gel particles are dried to form mesoporous sound-absorbing material particles. In step 4, the mesoporous sound-absorbing material particles are roasted.Type: GrantFiled: May 18, 2016Date of Patent: June 8, 2021Assignee: GOERTEK, INC.Inventor: Xiaodong Cao
-
Patent number: 11020575Abstract: Drug delivery devices and methods of administering drugs to patients are provided. A device (50) includes a reservoir (60) containing a drug (58). The reservoir (60) is defined by a wall (64) having a water-permeable portion, such that the water-permeable portion permits water to enter the device (50) and contact the drug (58). A restraining plug (56) closes off an opening of the device (50) such that transient microchannels (62) form between an elastic portion (54) of the device (50) and the restraining plug (56), upon the generation of a sufficient pressure within the reservoir (60), to release the drug (58) from the device (50). Methods of treating patients for neurogenic detrusor overactivity resulting from a spinal cord injury and/or for idiopathic overactive bladder and urinary incontinence are also described.Type: GrantFiled: February 1, 2018Date of Patent: June 1, 2021Assignee: TARIS Biomedical LLCInventors: Heejin Lee, Emily Abbate, Sarah Hocking, Dennis Giesing
-
Patent number: 10968286Abstract: The present invention relates to site-selective modification of polysaccharides at their reducing end by conjugation with a single aminoxy-Regioselective Addressable Functionalized Template (RAFT) peptide.Type: GrantFiled: December 18, 2018Date of Patent: April 6, 2021Assignee: B. G. Negev Technologies and Applications LtdInventors: Smadar Cohen, Ashraf Brik
-
Patent number: 10869842Abstract: A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.Type: GrantFiled: September 7, 2017Date of Patent: December 22, 2020Inventor: David P Summers
-
Patent number: 10868277Abstract: An organic light emitting diode (OLED) display panel includes a thin film transistor (TFT) array substrate; an OLED light-emitting layer; an encapsulation layer; an inducing layer disposed on a light-emitting side of the OLED light-emitting layer; a micro lens array film disposed over the inducing layer; and an organic hydrophobic layer disposed between the inducing layer and the micro lens array film. By providing the organic hydrophobic layer with strong hydrophobic performance, a surface with a large water contact angle is provided for a subsequent formation of the micro lens array film, thereby improving an optical coupling ratio of the micro lens, and improving luminous efficiency of the OLED light emitting layer.Type: GrantFiled: December 18, 2018Date of Patent: December 15, 2020Assignee: Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd.Inventor: Tianfu Guo
-
Patent number: 10821282Abstract: Disclosed herein is an implantable medical device for implantation against cardiac tissue in the administration of electrotherapy to the cardiac tissue. The device includes a distal end and a monolithic controlled release device. The distal end includes a housing structure and a cavity within the housing structure. The cavity opens exterior the implantable medical device via a distal opening. The monolithic controlled release device is within the cavity and proximal the distal opening. The monolithic controlled release device includes a distal face, a proximal face opposite the distal face, an outer circumferential surface extending between the distal face and the proximal face, and a spline-shaped inner lumen extending between the distal face and the proximal face and radially inward from the outer circumferential surface. The monolithic controlled release device further includes an active pharmaceutical ingredient.Type: GrantFiled: May 21, 2018Date of Patent: November 3, 2020Assignee: Pacesetter, Inc.Inventors: Tyler J. Strang, Benjamin F. James, IV, Matthew Malone
-
Patent number: 10820844Abstract: Wireless electrochemical measurements methods using minimally invasive micro-sensors that monitor response of cells to specific analytes are described. Micro-actuators integrated on a same chip as the micro-sensors are used to provide closed loop in-vivo local therapy on demand. An in-vivo bio-electronic system that can monitor the health of cell colonies and accordingly dispense corresponding therapeutic drugs is also described.Type: GrantFiled: July 21, 2016Date of Patent: November 3, 2020Assignees: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE TRUSTEES OF DARTMOUTH COLLEGEInventors: Axel Scherer, Arti Gaur
-
Patent number: 10751280Abstract: The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.Type: GrantFiled: September 12, 2018Date of Patent: August 25, 2020Assignee: NanoVault Medical LLCInventors: Willard W. Hennemann, Bryan L. Steelman, Thomas J. Webster
-
Patent number: 10716921Abstract: Disclosed are sheaths that comprise a first sheath member having a first passageway, a first length, and a first proximal end defined by a first valve apparatus configured to seal the first passageway, the first passageway having a first passageway diameter at a location in the first passageway; and a second sheath member coupled to the first sheath member, the second sheath member having a second passageway and a second length, the second passageway having a second passageway diameter at a location in the second passageway; where the first passageway and the second passageway are separate from each other and not co-axial, the first length is different from the second length, and the first and second sheath members are positioned beside each other for a portion of their first and second lengths.Type: GrantFiled: April 25, 2016Date of Patent: July 21, 2020Assignee: Endophys Holdings, LLCInventor: Phillip D. Purdy
-
Patent number: 10618998Abstract: This invention provides poly(alkylene carbonate)-based amphiphilic block copolymers, compositions comprising the same, e.g., micelles, and methods of use thereof. This invention further provides methods for preparing the poly(alkylene carbonate)-based amphiphilic block copolymers of the invention.Type: GrantFiled: November 12, 2015Date of Patent: April 14, 2020Assignee: Purdue Research FoundationInventors: You-Yeon Won, Seunggweon Hong, Hoyoung Lee, Jaeyoung Park, Jaewon Lee
-
Patent number: 10617300Abstract: Provided are implantable or surface mounted biomedical devices and related methods for interfacing with a target tissue. The devices have a substrate and device component supported by the substrate. The components of the device are specially configured and packaged to be ultra-thin and mechanically compliant. In particular, device thicknesses are less than 1 mm and have lateral dimensions between about 1 m and 10 mm, depending on the application. Delivery substrates may be incorporated to assist with device implantation and handling. The devices can be shaped to provide injection in a minimally invasive manner, thereby avoiding unnecessary tissue damage and providing a platform for long-term implantation for interfacing with biological tissue.Type: GrantFiled: February 11, 2014Date of Patent: April 14, 2020Assignees: The Board of Trustees of the University of Illinois, Washington UniversityInventors: John A. Rogers, Michael Raymond Bruchas, Robert Gereau, Jordan Gary McCall, Daniel Brenner, Tae-il Kim, Gunchul Shin, Jaewoong Jeong
-
Patent number: 10617797Abstract: The invention relates to the field of biotechnology and medicine, more precisely, to manufacturing technique of implantable medical devices (stents) containing organic lanthanum compound-based X-ray contrast agents distributed within the coating. The objective of this invention is the development of a biocompatible (and biodegradable) polymeric coating with glycolane on the surface of polymeric biodegradable vascular stents and other polymeric implants, which ensures, by means of introduction into a stent, satisfactory radiopacity both during stent installation in a patient and after installation, with a simultaneous additional positive effect provided by therapeutic properties of glycolane.Type: GrantFiled: December 18, 2015Date of Patent: April 14, 2020Assignee: LIMITED LIABILITY COMPANY “BIOSTEN”Inventors: Alla Nikolaevna Generalova, Anna Igorevna Prostyakova, Igor Ivanovich Pashkin, Vitaly Pavlovich Zubov, Dmitry Valeryevich Kapustin
-
Patent number: 10588350Abstract: An electronic cigarette includes an atomizer having a coil-less heating element having a heating section, two leads electrically connected to the heating section, and a liquid guiding structure. The liquid guiding structure includes two pads, a first pad and a second pad sandwiching at least a portion of the heating section. A gasket may be placed between a liquid supply and the first pad such that liquid is conducted from the liquid supply to the first pad.Type: GrantFiled: May 4, 2015Date of Patent: March 17, 2020Assignee: FONTEM HOLDINGS 1 B.V.Inventors: Fucheng Yu, Zhuoran Li
-
Patent number: 10575925Abstract: A method of forming an orthodontic aligner from an aligner digital model, the method comprising the steps of: (a) three-dimensionally printing an intermediate structure comprising fused filaments from a biocompatible thermoplastic according to the aligner digital model via fused deposition modelling; (b) coating the intermediate structure with a biocompatible translucent photopolymer; and (c) irradiating the coating with ultraviolet light to cure the coating on the intermediate structure, thereby forming the orthodontic aligner.Type: GrantFiled: May 23, 2017Date of Patent: March 3, 2020Assignee: Structo Pte LtdInventors: Hubertus Theodorus Petrus Van Esbroeck, Devansh Sharma, Siu Hon Lam, Kah Fai Chin, Boyle Suwono
-
Patent number: 10524895Abstract: There is disclosed a collagen construct comprising a plurality of elongate strips, wherein each strip contains a plurality of collagen fibres that are substantially aligned along the length of the respective strips, and the strips are braided or woven together to produce a collagen construct in the form of a rope that can be used for replacing tendons or ligaments, such as cruciate ligaments. Also disclosed is a method for making or producing the collagen construct from a collagen membrane having a plurality of collagen fibres being substantially aligned parallel to each other in a common direction. The membrane is cut along cut lines that are orientated substantially parallel to that common direction, thereby to separate elongate strips from the membrane. The strips are then braided or woven together to form the collagen construct.Type: GrantFiled: October 12, 2015Date of Patent: January 7, 2020Assignee: Orthocell LimitedInventor: Ming Hao Zheng
-
Patent number: 10517698Abstract: A method for securing a dental implant within a dental bone cavity is disclosed. The method may include inserting a dental wedge into the dental bone cavity and allowing bone tissues to grow toward and at least partially surround the dental wedge. Dental implantation systems for implementing the method are also disclosed. The system can include a dental wedge adapted to be inserted into a dental bone cavity.Type: GrantFiled: January 4, 2017Date of Patent: December 31, 2019Assignee: Zimmer Dental, Inc.Inventors: Suneel Ranga Sai Battula, Hai Bo Wen, Eneetra Patrice Livings, Michael Scott Collins
-
Patent number: 10517816Abstract: An orifice-free drug delivery device is provided. In an embodiment, the device includes a body having at least one water-permeable wall bounding a reservoir defined within the body. A drug formulation is disposed within the reservoir. The body has an elastic portion and at least one restraining plug closing off an opening of the body. The opening is in fluid communication with the reservoir, and the restraining plug contacts the elastic portion of the body and controls release of the drug from the device by the transient formation of one or more microchannels between the elastic portion of the body and the at least one restraining plug. The elastic portion may define an opening having an inner diameter, which is exceeded by the outer diameter of the restraining plug by at least 3%.Type: GrantFiled: October 31, 2017Date of Patent: December 31, 2019Assignee: TARIS BIOMEDICAL LLCInventor: Heejin Lee
-
Patent number: 10441528Abstract: The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.Type: GrantFiled: March 16, 2018Date of Patent: October 15, 2019Assignee: INTARCIA THERAPEUTICS, INC.Inventors: Thomas R. Alessi, Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine Manya Rohloff, Bing Yang
-
Patent number: 10433892Abstract: Provided is a material for preventing bone cement from leaking out from bone during packing of the bone cement into a bone fracture site. The bone cement can be prevented from leaking out from the bone by employing a three-dimensional structure produced from a material containing a polyhydroxyalkanoate, when packing the bone cement into the bone fracture site.Type: GrantFiled: March 26, 2013Date of Patent: October 8, 2019Assignees: National University Corporation Nagoya University, National University Corporation Nagoya Institute of TechnologyInventors: Hitoshi Hirata, Takanobu Nishizuka, Tadahiro Natsume, Toshihiro Kasuga
-
Patent number: 10383977Abstract: Polymeric grafts for treating damaged biological tissue that are formed from poly(glycerol sebacate) (PGS). The PGS grafts preferably comprise a bioactive agent comprising anti-inflammatory corticosteroids, anti-oxidants, anti-thrombotic agents and anti-platelet agents. The PGS grafts can also comprise a HMG-CoA reductase inhibitor.Type: GrantFiled: January 23, 2018Date of Patent: August 20, 2019Assignee: CorMatrix Cardiovascular, IncInventor: Robert G Matheny
-
Patent number: 10301376Abstract: Provided are combinations, compositions and kits containing a immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are methods for subcutaneous administration of immune globulin whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same IG-treatable disease or condition.Type: GrantFiled: March 16, 2009Date of Patent: May 28, 2019Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Richard Schiff, Heinz Leibl
-
Patent number: 10280265Abstract: A method can selectively prepare a compound of formula (IV), where each R1 and each R2 are independently selected from an alkyl group, an aryl group, a halogenated alkyl group, or a halogenated aryl group of 6 to 10 carbon atoms each R3 is an alkane-diyl group, and each R4 is hydrogen or an alkyl group. The method involves hydrosilylation of an organohydrogensiloxane oligomer with a carboxylic acid alkenyl ester using an iridium complex catalyst.Type: GrantFiled: December 5, 2016Date of Patent: May 7, 2019Assignee: Dow Corning CorporationInventors: Donald Eldred, Matthew Jeletic, Ryan Christopher Thomas
-
Patent number: 10272116Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: February 5, 2014Date of Patent: April 30, 2019Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 10265344Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: May 30, 2014Date of Patent: April 23, 2019Assignee: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: RE49967Abstract: Provided are combinations, compositions and kits containing a immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are methods for subcutaneous administration of immune globulin whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same IG-treatable disease or condition.Type: GrantFiled: May 27, 2021Date of Patent: May 14, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Richard Schiff, Heinz Leibl